Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor ...

Additionally, a 2023 study suggested that during the weight-loss phase of treatment ... patients taking a GLP-1 RA or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, but few ...

REUTERS Eli Lilly’s drug is called “triple G” because it mimics GLP-1, the appetite-suppressing hormone GIP and glucagon, a hormone that helps control blood sugar levels. Phase 3 trials are ...

--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and ...

Kailera unveiled the Zepbound-matching phase 2 data for KAI-9531 at the start of this year. As Fierce Biotech noted at the time, Zepbound—also a dual GIP and GLP-1 receptor agonist—showed ...

Viking Therapeutics is expected to lead this group with its dual GLP-1RA/gastric inhibitory polypeptide receptor (GIP-R) agonist, VK-2735, which is in Phase II for obesity with an oral route of ...

gastric inhibitory polypeptide (GIP), in addition to GLP-1. This drug has shown a maximum weight loss of 20 percent at the highest dose strength after 72 weeks. CagriSema combines semaglutide with ...

Many design characteristics of the Study, also referred to as Study GLP-1-H24-3, are similar to Lexaria's initial GLP-1 human pilot study #1, investigating the dual agonist GLP-1/GIP drug ...

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...